We integrate:

Functional anatomy & NTCP modeling – defining the bulboclitoris and related structures as organs at risk, quantifying dose–response relationships, and building normal‑tissue complication probability (NTCP) models that can be used directly in treatment planning.

Multiscale biologic profiling – applying spatial transcriptomics, imaging biomarkers, microbiome analyses, and radiomics to understand how radiation and the menopausal transition jointly reshape neurovascular, erectile and vaginal tissues.

Interventions & devices – co‑developing estrogen‑eluting vaginal hydrogels, hydrogel spacers, and other biomaterials to prevent injury (e.g. stenosis/adhesions), preserve lubrication and elasticity, and restore sensation after pelvic radiotherapy.

LGBTQ+ and sexual minority survivorship – characterizing sexual function and pleasure in lesbian, gay, bisexual, transgender, and nonbinary cancer survivors (e.g., after prostate, colorectal, and pelvic treatments) and designing inclusive interventions and care pathways.

Transparency & equity – empirically studying how conflicts of interest, pricing, and communication practices shape trust, decision‑making, and access to high‑value, sexual‑health–preserving care.

Who we are

The program is led by Dr. Deborah Marshall, a board-certified Radiation Oncologist, Menopause Society Certified Practitioner, and NIH High‑Risk, High‑Reward Early Independence Awardee whose team has secured more than $2 million in research funding as Principal Investigator and authored over 70 peer‑reviewed papers in journals including JAMA, JAMA Oncology, CA: A Cancer Journal for Clinicians, and The Lancet Oncology. Our group bridges radiation oncology, population health science, women’s health, biomedical engineering, and ethics to train the next generation of scientists and clinicians in oncosexual health.